capecitabine has been researched along with Epithelial Ovarian Cancer in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Brady, WE; Christensen, H; Dark, G; Feeney, A; Frumovitz, M; Ganesan, R; Gershenson, DM; Gore, M; Hackshaw, A; Kehoe, S; Ledermann, J; Lord, R; Mackean, M; McCluggage, WG; Montes, A; Penson, RT; Perren, T; Reed, N; Rustin, G; Summers, J; Wilkinson, N; Zaino, R | 1 |
1 trial(s) available for capecitabine and Epithelial Ovarian Cancer
Article | Year |
---|---|
An international, phase III randomized trial in patients with mucinous epithelial ovarian cancer (mEOC/GOG 0241) with long-term follow-up: and experience of conducting a clinical trial in a rare gynecological tumor.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Carboplatin; Carcinoma, Ovarian Epithelial; Female; Follow-Up Studies; Humans; Internationality; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Cystic, Mucinous, and Serous; Ovarian Neoplasms; Oxaliplatin; Paclitaxel; Progression-Free Survival; Quality of Life; Response Evaluation Criteria in Solid Tumors; Survival Rate; Young Adult | 2019 |